Vaxart, Inc. Severance Costs
Vaxart, Inc. (VXRT) reported Severance Costs of $500.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SeveranceCosts1 · last filed 2024-03-14
- Vaxart, Inc. severance costs for the quarter ending 2023-03-31 was $732.00K.
- Vaxart, Inc. severance costs for fiscal 2023 was $500.00K.
| Period end | Severance Costs 3 month | Severance Costs 12 month |
|---|---|---|
| 2023-12-31 | $500.00K 10-K · filed 2024-03-14 | |
| 2023-03-31 | $732.00K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |